Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX®B/E HIV vaccine trial, Bangkok, Thailand

AIDS

Volumn 18, Issue 2, 2004, Pages 311-316

  Vanichseni, Suphak ^a   Tappero, Jordan W ^d,e   Pitisuttithum, Punnee ^b   Kitayaporn, Dwip ^b   Mastro, Timothy D ^e   Vimutisunthorn, Eiam ^c   Van Griensven, Frits ^d,e   Heyward, William L ^f   Francis, Donald P ^f   Choopanya, Kachit ^a  

^a Bangkok Vaccine Evaluation Group   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Bangkok Metropolitan Administration   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f VaxGen Inc   (United States)

Author keywords

AIDS vaccines; Bangkok; gp120 vaccine; HIV; HIV vaccine efficacy trial; HIV vaccines; Injection drug users; Thailand

Indexed keywords

CENTRAL STIMULANT AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANQUILIZER;

ACADEMIC ACHIEVEMENT; ADULT; ANAMNESIS; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PATIENT SELECTION; PHARMACIST; PRIORITY JOURNAL; PRISON; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; STANDARD; THAILAND;

ADULT; AIDS VACCINES; ATTITUDE TO HEALTH; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION; PATIENT SELECTION; QUESTIONNAIRES; RISK-TAKING; SEXUAL PARTNERS; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND;

EID: 10744231887     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401230-00022     Document Type: Article

References (24)

1. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, Vanichseni S, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991, 5(suppl 2):S71-S85.
2. Esparza, J, Osmanov S, Kallings LO, Wigzell H. Planning for HIV vaccine trails: the World Health Organization perspective. AIDS 1991, 5(suppl 2):S159-S163.
3. Heyward WL, Osmanov S, Esparza J. Establishment of WHO-sponsored field sites for HIV vaccine evaluation in developing countries. Antibiot Chemother 1996, 48:139-144.
4. Phoolcharoen W, Ungchusak K, Sittitrai W, Brown T. Thailand: lessons from a strong national response to HIV/AIDS. AIDS 1998, 12:S123-S135.
5. Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des Jarlais DC, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 2001, 15:397-405.
6. MacQueen KM, Vanichseni S, Kitayaporn D, Lin LS, Buavirat A, Naiwatanakul T, et al. Willingness of injecting drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr 1999, 21:243-251.
7. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001, 15:683-691.
8. Hu DJ, Subbarao S, Vanichseni S, Mock PA, van Griensven F, Nelson R, et al. Higher viral loads and other risk factors associated with HIV-1 seroconversion during a period of high incidence among injection drug users in Bangkok. J Acquir Immune Defic Syndr 2002, 30:240-247.
9. Subbarao S, Vanichseni S, Hu DJ, Kitayaporn D, Choopanya K, Raktham S, et al. Genetic characterization of HIV-1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses 2000, 16: 699-707.
10. Phan K-O, Callahan ME, Vanichseni S, Hu DJ, Raktham S, Young NL, et al. A comparison of full-length gp120 from incident HIV-1 subtype E and B infections in Bangkok injecting drug users to prototype E and B strains that are components of a candidate vaccine. AIDS Res Hum Retroviruses 2000: 16,1445-1450.
11. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998, 14(suppl 3):S277-S289.
12. Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, et al. Advancing AIDSVAX™ to phase 3. Safety, immunogenicity and plans for phase 3. AIDS Res Hum Retroviruses 1998, 14(suppl 3):S325-S331.
13. Pitisuttithum P, Chernow M, Berman P, Francis D, Phonrat B, Suntharasamai P, et al. Initial report of a phase I/II trial of AIDSVAX™B/E rgp120 HIV vaccine, Bangkok, Thailand. XIII International Conference on AIDS. Durban, July 2000 [poster WePpA 1362].
14. Martin M, Mansakul W, Tappero J, Sangkum U, Vanichseni S, Prasitiphol B, et al. Care and treatment of HIV-infected persons during a HIV vaccine efficacy trial, Bangkok, Thailand. Session 62-Clinical trials: risk factors. AIDS Vaccine 2003 Conference: New York, 18-21 September [poster no. 502].
15. Subbarao S, Limpakarnjanarat K, Mastro TD, Bhumisawasdi J, Warachit P, Jayavasu C, et al. HIV-1 in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity. AIDS Res Hum Retroviruses 1998, 14:319-327.
16. Pitisuttithum P, Migasena S, Laothai A, Suntharasamai P, Kumpong C, Vanichseni S. Risk behavior and comprehension among intravenous drug users volunteering for HIV vaccine trails. J Med Assoc Thai 1997, 80:47-50.
17. Kilmarx PH, Ramjee G, Kitayaporn D, Kunasol P. Protection of human subjects' rights in HIV-preventive clinical trials in Africa and Asia: experiences and recommendations. AIDS 2001, 15(suppl 5):S73-S79.
18. van Griensven F, Vanichseni S, Kitayaporn D, Suntharasamai P, Tappero JW, Sangkum U, et al. HIV risk behavior change among injecting drug users in the AIDSVAX®B/E HIV vaccine efficacy trial in Bangkok, Thailand. AIDS 2004, 18:in press.
19. Kitayaporn D, Vanichseni S, Mastro TD, Raktham S, Vaniyapongs T, Des Jarlais DC, et al. Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:289-295.
20. MacQueen KM, Buchbinder S, Douglas JM, Judson FN, McKirnan DJ, Bartholow B. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection. AIDS Res Hum Retroviruses 1994, 10(suppl 2):S261-S264.
21. Choopanya K, Des Jarlais DC, Vanichseni S, Kitayporn D, Mock PA, Raktham S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok J Acquir Immune Defic Syndr 2002, 29:86-94.
22. Esparza J, Burke D. Epidemiological considerations in planning HIV preventive vaccine trials. AIDS 2001, 15(suppl 5):S49-S57.
23. Wasi C, Herring B, Raktham S, Vanichseni S, Mastro TD, Young NL, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995, 9: 843-849.
24. Kalish ML, Baldwin A, Raktham S, Wasi C, Luo C-C, Schochetman G, et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS 1995, 9:851-857.